Entries tagged "ImClone"

You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "ImClone."

12 result(s) displayed (1 - 12 of 12)

Carl Icahn's activist campaigns

Carl Icahn ended his 10-day truce with Lions Gate Entertainment Corp. by instituting another tender offer for shares in the studio that the activist investor doesn't already own. Continue reading

Posted on July 20, 2010 1:20 PM

Big Pharma: Pfizer, Merck, Wyeth and more

The pharmaceutical industry has seen a ton of deals over the past few years, some $230 billion in M&A activity from the top 10 pharmaceutical companies alone since the beginning of 2007. Continue reading

Posted on March 9, 2010 9:13 AM

Dialoguing at Deutsche

Bruce Evans takes the reins of Deutsche's M&A effort at a difficult time. Continue reading

Posted on March 20, 2009 1:44 PM

The big trial

From VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Continue reading

Posted on March 6, 2009 11:29 AM

Out of rhythm

Boston Scientific snatched cardiac implant maker Guidant away from healthcare giant Johnson & Johnson three years ago and hasn't breathed easily since. Continue reading

Posted on January 23, 2009 12:56 PM

They need a new drug

Expect Big Pharma to go shopping in biotechland, but with an eye for fire sales. Continue reading

Posted on January 9, 2009 2:10 PM

ImClone

Massachusetts' State-Boston Pension Fund has stepped in with a lawsuit to block Eli Lilly's $6.5 billion deal for ImClone. Continue reading

Posted on October 27, 2008 4:35 PM

Spread too far

Amid turmoil, risk arbs have absorbed a lot of bad news, but some strategic deals look likely to close, and deal demand may be building. Continue reading

Posted on October 17, 2008 3:34 PM

Latham gilds Lilly's ImClone offer

Deutsche Bank AG's Jim Stynes, Michael Cohen and Bruce Evans were among the financial advisers. Continue reading

Posted on October 10, 2008 12:35 PM

Risk Arb update

Uncertainty in banking and M&A credit markets have hammered share prices of targets of hostile bids, along with the broader stock market. Continue reading

Posted on September 26, 2008 5:15 PM

Bristol taps Citi, Cravath for advice on ImClone

Citigroup, Morgan Stanley and Cravath advise Bristol as it pursues ImClone with a $4.5 billion offer. Continue reading

Posted on August 29, 2008 11:30 AM

Carl Icahn, Icahn Enterprises chairman

Icahn's long career as an activist investor includes governance battles with RJR Nabisco, Viacom, Time Warner, Motorola and many other public companies. Continue reading

Posted on July 17, 2008 7:05 AM

Movable Type search results powered by Fast Search